Nauck, Michael A.
Universitätsmedizin Greifswald · St. Josef-Hospital · Katholisches Klinikum Bochum · Ruhr University Bochum
103 papers on CoChatORCID 0000-0002-5749-6954
Most cited papers
- Verified
Incretin‐based glucose‐lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio‐vascular outcome trials
Nauck, M. A., Meier, J. J., & Schmidt, W. E. (2017) · Diabetes, Obesity and Metabolism
Diabetes Treatment and ManagementPancreatic and Hepatic Oncology Research
Cited by 19
- Verified
Accurate Measurements of Gastric Emptying and Gastrointestinal Symptoms in the Evaluation of Glucagon-like Peptide-1 Receptor Agonists
Jalleh, R. J., Jones, K. L., Nauck, M., & Horowitz, M. (2023) · Annals of Internal Medicine
Gastrointestinal motility and disordersDiabetes Treatment and Management
Cited by 18
- Verified
Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists
Nauck, M. A., & Horowitz, M. (2023) · The Lancet
Diabetes Treatment and ManagementPharmacology and Obesity Treatment
Cited by 16
- Verified
Therapy of Type 2 Diabetes
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. (2022) · Experimental and Clinical Endocrinology & Diabetes
Diabetes Treatment and ManagementDiabetes Management and Research
Cited by 12
- Verified
P2857Increase in pulse rate with semaglutide did not result in increased adverse cardiac events in subjects with type 2 diabetes in the SUSTAIN 6 cardiovascular outcomes trial
Seufert, J., Nauck, M., Rosenstock, J., Hansen, T., Vrazic, H., & Vilsboll, T. (2018) · European Heart Journal
Diabetes Treatment and ManagementBlood Pressure and Hypertension Studies
Cited by 9
- Verified
Another milestone in the evolution of GLP-1-based diabetes therapies
Nauck, M. A., Quast, D. R., & Meier, J. J. (2021) · Nature Medicine
Diabetes Treatment and ManagementPharmacology and Obesity Treatment
Cited by 7
- Verified
Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis
Nicholls, S. J., Pavo, I., Bhatt, D. L., Buse, J. B., Del Prato, S., Franco, D. R., Kahn, S. E., Lincoff, A. M., Martins, R. F., McGuire, D. K., et al. (2026) · European Journal of Preventive Cardiology
Diabetes Treatment and ManagementHeart Failure Treatment and Management
Cited by 0
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free